设为首页 加入收藏

TOP

Nivestim 48 MU/ 0.5 ml solution for injection/infusion Filgr
2014-12-02 10:37:56 来源: 作者: 【 】 浏览:1007次 评论:0

For doctors

 

What is it and how is it used?

What Nivestim is

Nivestim contains the active substance filgrastim. It belongs to a group of proteins called cytokines and is very similar to a natural protein (granulocyte-colony stimulating factor [G-CSF]) produced by your own body. Filgrastim stimulates the bone marrow (the tissue where new blood cells are made) to produce more blood cells, especially certain types of white cells. White cells are important as they help your body fight infection.

What Nivestim is used for
Your doctor has prescribed Nivestim for you to help your body make more white blood cells. Your doctor will tell you why you are being treated with Nivestim.
Nivestim is useful in several different conditions which are:

What do you have to consider before using it?

Do not use Nivestim

Take special care with Nivestim

You may need to have regular blood tests whilst being treated with Nivestim to count the number of neutrophils and other white blood cells in your blood. This will tell your doctor how the treatment is working and will also indicate if treatment needs to be continued.

Using other medicines
You should not receive Nivestim in the 24 hours before and the 24 hours after receiving chemotherapy. Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.

Pregnancy and breast-feeding
Ask your doctor or pharmacist for advice before taking any medicine.
Filgrastim has not been tested in pregnant women. It is important to tell your doctor if you are pregnant, think you may be pregnant or plan to get pregnant, as your doctor may decide that you should not use this medicine. Filgrastim could affect your ability to become pregnant or stay pregnant.
It is unknown whether filgrastim passes over to the breast milk. Therefore, your doctor may decide that you should not use this medicine if you are breast-feeding.

Driving and using machines
Filgrastim has negligible influence on the ability to drive and use machines. If the patient is experiencing fatigue, caution is advised when driving a car or operating machinery.

Important information about some of the ingredients of Nivestim
This medicine contains sorbitol (E420). If you have been told by your doctor that you have an intolerance to some sugars (fructose), contact your doctor before taking this medicine. This medicine also contains sodium less than 1mmol sodium (23 mg) per dose, i.e. essentially ‘sodium-free’.

How is it used?

Always use Nivestim exactly as your doctor tells you to.
This medicine is given by injection, either through an intravenous infusion (drip) or by a subcutaneous injection into the tissue just under the skin.
If you are receiving this medicine by subcutaneous injection, your doctor may suggest that you learn how to give yourself the injections. Your doctor or nurse will give you instructions on how to do this (see end of leaflet for self administration information). Do not attempt to self-administer without this training. Some of the information you require is given at the end of this leaflet, but proper treatment of your disease requires close and constant co-operation with your doctor. The amount of Nivestim you need, will depend on the condition you are taking Nivestim for and on your bodyweight.

Nivestim and neutropenia associated with chemotherapy

The usual dose for adults and children is 0.5 million units (5 micrograms) per kilogram of bodyweight each day. For example, if you weigh 60 kg your daily dose will be 30 million units (300 micrograms). Your treatment will usually last for about 14 days. In some disease types however, longer treatment lasting up to about one month may be required.

Nivestim and bone marrow transplantation

The normal starting dose is 1 million units (10 micrograms) per kilogram of bodyweight each day given as an infusion. For example, if you weigh 60 kg your daily dose will be 60 million units (600 micrograms). You will normally receive your first dose of Nivestim at least 24 hours after your chemotherapy but within 24 hours of receiving your bone marrow transplantation. Your doctor may then test your blood to tell how well your treatment is working and how long it should last.

Nivestim and severe chronic neutropenia

The normal starting dose is between 0.5 million (5 micrograms) and 1.2 million (12 micrograms) units per kilogram bodyweight each day in a single or divided dose. Your doctor may then test your blood to see how well your treatment is working and to find the dose that is best for you. Long-term treatment with Nivestim is required for neutropenia.

Nivestim and neutropenia in patients with HIV infection

The normal starting dose is between 0.1 (1 micrograms) and 0.4 million units (4 micrograms) per kilogram bodyweight each day. Your doctor may test your blood at regular intervals to see how well the treatment is working and to decide on the dose necessary. Once the number of white cells in your blood have returned to normal it may be possible to reduce the dose frequency to less than once per day. Long term treatment with Nivestim may be required to maintain a normal number of white cells in your blood.

Nivestim and peripheral blood stem cell transplantation

If you are donating stem cells for yourself, the usual dose is 0.5 million (5 micrograms) to 1 million units (10 micrograms) per kilogram bodyweight each day. Nivestim treatment will last for up to 2 weeks. Your doctor will monitor your blood to determine the best time to collect the stem cells.
If you are acting as a stem cell donor for another person, the usual dose is 1 million units per kilogram bodyweight each day. Nivestim treatment will last for 4 to 5 days.

If you use more Nivestim than you should
If you use more Nivestim than you should, contact your doctor or pharmacist as soon as possible.

If you forget to use Nivestim
If you have forgotten to inject a dose, speak to your doctor or pharmacist to find out when you should inject the next dose. Do not use a double dose to make up for a forgotten injection.

If you stop using Nivestim
Your doctor will tell you when to stop using Nivestim. It is quite normal to have a number of courses of Nivestim treatment.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

What are possible side effects?

Like all medicines, Nivestim can cause side effects, although not everyone gets them.

Allergic-type reactions to filgrastim, including skin rash, raised areas of the skin that itch and anaphylaxis (weakness, drop in blood pressure, difficulty breathing and swelling of the face) have been reported. If you think you are having this type of reaction, stop your Nivestim injection and get medical help immediately.

Increased spleen size and very rare cases of spleen ruptures have been reported. Some cases of rupture of the spleen were fatal.
It is important that you contact your doctor immediately if you experience pain in the upper left side of the abdomen or left shoulder painsince this may relate to a problem with your spleen.

It is also very important that you call your doctor if you think you may have an infection. There are many ways an infection may show itself. You should watch for a temperature of 37.8 °C or above, chills or other signs of infection, such as a rash, sore throat, diarrhoea, ear-ache, difficult or painful breathing or problems such as cough or wheezing. These symptoms could be signs of severe lung side effects, like pneumonia and respiratory distress syndrome in adults, which may be fatal. If you have a fever or any of these symptoms, contact your doctor immediately and go straight to your hospital.
If you have Sickle Cell Disease, make sure that you tell your doctor before you start taking Nivestim. Sickle cell crisis has happened in some patients with Sickle Cell Disease who have been given filgrastim.

The frequency of possible side effects listed below is defined using the following convention: Very common (affects more than 1 user in 10)
Common (affects 1 to 10 users in 100)
Uncommon (affects 1 to 10 users in 1,000)
Rare (affects 1 to 10 users in 10,000)
Very rare (affects less than 1 user in 10,000)

Very common side effects

Common side effects

Uncommon side effects

Rare side effects

The side effects that may be experienced by you if you are acting as a stem cell donor for another person are:

Very common side effects

Common side effects

Uncommon side effects

If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

How should it be stored?

Keep out of the reach and sight of children.

Do not use Nivestim after the expiry date which is stated on the outer carton and on the pre-filled syringe after EXP. The expiry date refers to the last day of that month.

Store and transport refrigerated (2°C – 8°C). Do not freeze. Keep the pre-filled syringe in the outer carton in order to protect from light.
The syringe can be removed from the refrigerator and left at room temperature for a single period of maximum 7 days (but not above 25°C).

Do not use Nivestim if you notice it is cloudy or there are particles in it.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.

↑ back to table of contents ↑

For doctors

What is it?

Nivestim is a solution for injection or infusion (drip into a vein) that contains the active substance filgrastim. It is available as prefilled syringes (12, 30 or 48 million units).

Nivestim is a ‘biosimilar’ medicine. This means that Nivestim is similar to a biological medicine (the ‘reference medicine’) that is already authorised in the European Union (EU) and contains the same active substance as the reference medicine. The reference medicine for Nivestim is Neupogen. For more information on biosimilar medicines, see the question-and-answer document here.

What is it used for?

Nivestim is used to stimulate the production of white blood cells in the following situations:

Nivestim can also be used in people who are about to donate blood stem cells for transplant, to help release these cells from the bone marrow.

The medicine can only be obtained with a prescription.

How is it used?

Nivestim is given by injection under the skin or infusion into a vein. How it is given, the dose and the duration of treatment depend on why it is being used, the patient’s body weight and the response to treatment. Nivestim is usually given in a specialised treatment centre, although patients who receive it by injection under the skin may inject themselves once they have been trained appropriately. For more information, see the Package Leaflet.

How does it work?

The active substance in Nivestim, filgrastim, is very similar to a human protein called granulocyte colony stimulating factor (G-CSF). Filgrastim is produced by a method known as ‘recombinant DNA technology’: it is made by a bacterium that has received a gene (DNA), which makes it able to produce filgrastim. The replacement acts in the same way as naturally produced G-CSF by encouraging the bone marrow to produce more white blood cells.

How has it been studied?

Nivestim was studied to show that it is comparable to the reference medicine, Neupogen. Nivestim was compared with Neupogen in one main study involving 279 women with breast cancer who were being treated with anticancer medicines. The main measure of effectiveness was based on the reduction in the length of time that the patients had severe neutropenia.

What benefits has it shown during the studies?

Studies carried out with Nivestim showed that it was comparable to Neupogen. In the main study, the patients who received Nivestim had severe neutropenia for a similar length of time as the patients who received Neupogen.

What is the risk associated?

The most common side effect with Nivestim (seen in more than 1 patient in 10) is musculoskeletal pain (pain in the muscles and bones). Other side effects may be seen in more than 1 patient in 10, depending on the condition that Nivestim is being used for. For the full list of all side effects reported with Nivestim, see the Package Leaflet.

Nivestim should not be used in people who may be hypersensitive (allergic) to filgrastim or any of the other ingredients.

Why has it been approved?

The CHMP decided that, in accordance with EU requirements, Nivestim has been shown to have a comparable quality, safety and efficacy profile to Neupogen. Therefore, the CHMP’s view was that, as for Neupogen, the benefit outweighs the identified risk. The Committee recommended that Nivestim be given marketing authorisation.

Further information

The European Commission granted a marketing authorisation valid throughout the EU for Nivestim to Hospira UK Limited on 8 June 2010. The marketing authorisation is valid for five years, after which it can be renewed.

For more information about treatment with Nivestim, read the Package Leaflet (also part of the EPAR) or contact your doctor or pharmacist.

This summary was last updated in 06-2010.

↑ back to table of contents ↑
 

Name

 

Nivestim 48 MU/ 0.5 ml solution for injection/infusion

 

Composition

 

Each ml of solution for injection or infusion contains 96 million units [MU] (960 micrograms) of filgrastim*.

Each pre-filled syringe contains 48 million units (MU) (480 micrograms) of filgrastim in 0.5 ml (0.96 mg/ml).

*recombinant methionyl granulocyte-colony stimulating factor [G-CSF] produced in Escherichia Coli (BL21)by recombinant DNA technology.

Excipient(s): Each ml of solution contains 50 mg of sorbitol.
For a full list of excipients, see section 6.1.

 

Pharmaceutical Form

 

Solution for injection/infusion (injection/ infusion).

Clear, colourlesss solution.

 

Are you an Healthcare Professional? Access professional drug leaflets on Diagnosia.com!

 

以下是“全球医药”详细资料
Tags: 责任编辑:admin
】【打印繁体】【投稿】【收藏】 【推荐】【举报】【评论】 【关闭】 【返回顶部
分享到QQ空间
分享到: 
上一篇Nivestim 12 MU/ 0.2 ml solution.. 下一篇Nivestim 30 MU/ 0.5 ml solution..

相关栏目

最新文章

图片主题

热门文章

推荐文章

相关文章

广告位